--- title: "Xintian Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 16.1809 million yuan, a year-on-year decrease of 73.47%" type: "News" locale: "en" url: "https://longbridge.com/en/news/263461118.md" description: "According to the Zhitong Finance APP, Xintian Pharma released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 559 million yuan, a year-on-year decrease of 15.47%. The net profit attributable to shareholders of the listed company was 16.1809 million yuan, a year-on-year decrease of 73.47%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 13.5545 million yuan, a year-on-year decrease of 67.93%" datetime: "2025-10-30T08:43:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/263461118.md) - [en](https://longbridge.com/en/news/263461118.md) - [zh-HK](https://longbridge.com/zh-HK/news/263461118.md) --- # Xintian Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 16.1809 million yuan, a year-on-year decrease of 73.47% According to the Zhitong Finance APP, Xintian Pharma (002873.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 559 million yuan, a year-on-year decrease of 15.47%. The net profit attributable to shareholders of the listed company was 16.1809 million yuan, a year-on-year decrease of 73.47%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 13.5545 million yuan, a year-on-year decrease of 67.93% ### Related Stocks - [002873.CN](https://longbridge.com/en/quote/002873.CN.md) ## Related News & Research - [16:51 ETBeverly Hills MD ProRetinol Age Rewind x3 Officially Launches: A New Era of Gentle, Slow-Released Retinol Skincare Backed by Plastic Surgeons](https://longbridge.com/en/news/286966075.md) - [Orkla’s OV UK Buys Phoenix Brands to Boost Sweet Ingredients Footprint](https://longbridge.com/en/news/286763926.md) - [AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain](https://longbridge.com/en/news/286879044.md) - [](https://longbridge.com/en/news/286948461.md) - [BCAL Diagnostics Expands National Access to Early Cancer Detection Blood Tests](https://longbridge.com/en/news/286850851.md)